Anika Therapeutics Q2 Adj EPS $0.06 Beats $(0.27) Estimate, Sales $44.30M Beat $40.56M Estimate
Portfolio Pulse from bharat@benzinga.com
Anika Therapeutics reported Q2 earnings of $0.06 per share, beating the analyst consensus estimate of $(0.27) by 122.22%. The company also reported quarterly sales of $44.30 million, beating the estimate of $40.56 million by 9.23%. This represents a 150% increase in earnings and a 11.71% increase in sales compared to the same period last year.
August 08, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anika Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Anika Therapeutics reported Q2 earnings and sales that beat estimates, which is typically a positive signal for the stock. The significant increase in earnings and sales compared to the same period last year further strengthens this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100